Similar to obesity, the prevalence of MS—or comparable cardiovascular risk profiles—tends to increase with age among ALL survivors, is more common in females than males, and has been associated with prior exposure to cranial radiotherapy (CRT) and/or growth hormone (GH) abnormalities [40] (Table 2). The gene discussed is GH1; the disease is myeloid sarcoma.